Valuation: Inventiva

Market Cap 912M 1.04B 843M 775M 1.46B 100B 1.49B 10.08B 3.95B 49.1B 3.91B 3.82B 169B P/E 2026 *
-5.29x
P/E 2027 * -4.93x
Enterprise Value 745M 849M 688M 633M 1.19B 81.91B 1.21B 8.23B 3.23B 40.08B 3.19B 3.12B 138B EV / Sales 2026 *
111x
EV / Sales 2027 * 2.8x
Free-Float
89.08%
Yield 2026 *
-
Yield 2027 * -
1 day-3.26%
1 week+3.07%
Current month+19.88%
1 month+26.35%
3 months-19.16%
6 months-25.05%
Current year-2.15%
1 week 3.66
Extreme 3.66
4.08
1 month 2.88
Extreme 2.88
4.08
Current year 2.88
Extreme 2.88
6.2
1 year 2.64
Extreme 2.645
6.2
3 years 1.43
Extreme 1.434
6.2
5 years 1.43
Extreme 1.434
13.18
10 years 1.43
Extreme 1.434
16.3
Manager TitleAgeSince
Chief Executive Officer 53 2025-09-30
Director of Finance/CFO 59 2026-04-21
Chief Tech/Sci/R&D Officer 56 2025-07-29
Director TitleAgeSince
Director/Board Member 75 2017-01-31
Director/Board Member 63 2019-05-26
Director/Board Member 52 2024-04-30
Date Insider Type Main position Quantity % Market Cap.
1/10/26 Others

General Counsel

25,000 0.0131%
1/10/26 Others

Chief Operating Officer

25,000 0.0131%
1/10/26 Others

Executive/Senior Manager

50,000 0.0262%
Change 5-day change 1-year change 3-year change Capi.($)
-3.26%+3.07%+40.11%+7.07% 1.08B
+0.21%-0.79%+53.17%+57.39% 53.83B
+5.37%+3.31%+50.39%+83.65% 52.1B
-1.20%-1.94%+4.35%+402.68% 23.48B
+0.74%+2.32%-16.23%-14.44% 23.13B
+3.46%+2.52%+34.01%-5.41% 19.36B
-1.18%-2.97%+30.12%-33.30% 17.56B
-1.67%-6.00%+163.95%+284.69% 15.2B
+3.62%0.00%+29.70%+643.91% 14.83B
-0.70%-0.91%+24.87%+179.47% 14.06B
Average +0.54%-1.13%+41.44%+160.57% 23.46B
Weighted average by Cap. +1.45%-1.47%+41.46%+137.60%

Financials

2026 *2027 *
Net sales 6.73M 7.68M 6.22M 5.72M 10.8M 741M 10.97M 74.41M 29.17M 362M 28.84M 28.21M 1.25B 109M 124M 100M 92.29M 174M 11.94B 177M 1.2B 470M 5.84B 465M 455M 20.13B
Net income -150M -171M -138M -127M -240M -16.46B -244M -1.65B -648M -8.05B -641M -627M -27.75B -102M -117M -94.65M -87.05M -164M -11.27B -167M -1.13B -444M -5.51B -439M -429M -18.99B
Net Debt -168M -191M -155M -142M -269M -18.43B -273M -1.85B -726M -9.02B -718M -702M -31.07B -608M -694M -562M -517M -975M -66.88B -991M -6.72B -2.63B -32.72B -2.6B -2.55B -113B
Logo Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.
Employees
73
Date Price Change Volume
26-07-20 €3.860 -3.26% 342,802
26-07-17 €3.990 +4.31% 440,690
26-07-16 €3.825 -1.16% 194,994
26-07-15 €3.870 +1.31% 246,378
26-07-14 €3.820 +2.00% 357,604
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.860EUR
Average target price
9.634EUR
Spread / Average Target
+149.60%

Quarterly revenue - Rate of surprise